Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kuo-Hsuan Hsu
The Association of Acquired T790M Mutation With Clinical Characteristics After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Cancer Research and Treatment
Cancer Research
Oncology
Related publications
Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
OncoTargets and Therapy
Oncology
Pharmacology
Impact of Epidermal Growth Factor Receptor Gene Expression Level on Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Patients Taking First-Line Epidermal Growth Factor Receptor–tyrosine Kinase Inhibitors
Tumor Biology
Medicine
Cancer Research
Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Journal of Cancer
Oncology
Pseudoprogression and Rapid Response to Pembrolizumab in a Patient With Advanced Lung Adenocarcinoma With Loss of Epidermal Growth Factor Receptor Gene Mutation After Tyrosine Kinase Inhibitor Therapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance
British Journal of Cancer
Cancer Research
Oncology
Polo-Like Kinase 1 Inhibition Diminishes Acquired Resistance to Epidermal Growth Factor Receptor Inhibition in Non-Small Cell Lung Cancer With T790M Mutations
Oncotarget
Oncology
Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report
Oncology Letters
Cancer Research
Oncology
